RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance™ Surgical Robotic System at the 46th AAGL Global Congress on Minimally Invasive Gynecologic Surgery (MIGS). The congress will be held November 12-16, 2017 in the Washington, DC area at the Gaylord National Resort and Convention Center at National Harbor.
“AAGL is the leading association promoting minimally invasive gynecologic surgery worldwide,” said Mohan Nathan, Vice President of Global Marketing at TransEnterix. “The recent US market clearance of Senhance includes the field of laparoscopic gynecology. The AAGL congress is an opportunity to engage with leading gynecologists about the first surgical robotic system that brings haptic force feedback, eye-sensing camera control and responsible economics through reusable instrumentation.”
TransEnterix will host a breakfast symposium for attendees titled, “Clinical Experience of the Senhance Surgical Robotic System in Gynecology” on Tuesday, November 14 at 7am ET. The keynote speaker will be Dr. Salvatore Gueli Alletti from the Agostino Gemelli University Polyclinic in Rome, Italy. Registration to attend this symposium is through the AAGL registration process.
The Senhance is available for surgeon demonstrations at the congress during exhibition hours on Tuesday, November 14 and Wednesday, November 15 from 9am to 3pm ET. Surgeons may schedule system demonstrations by signing up at the TransEnterix booth (#633). Those interested in attending the conference may register through the AAGL via https://www.aagl.org/globalcongress/.
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The Company is focused on the commercialization of the Senhance™ Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Company also developed the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System is available for sale in the US, the EU and select other countries. For more information, visit the TransEnterix website at www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and includes whether the AAGL congress is an opportunity to engage with leading gynecologists about the first surgical robotic system that brings haptic force feedback, eye-sensing camera control and responsible economics through instrumentation to robotics. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 7, 2017 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.